Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
Mesoblast, a global leader in allogeneic cellular medicines, has appointed Lyn Cobley to its Board of Directors. Cobley brings over 30 years of financial services experience, having served as CEO of Westpac Institutional Bank and Group Treasurer of Commonwealth Bank of Australia.
The appointment follows Mesoblast's recent FDA approval of Ryoncil®. Cobley currently serves as a director of Commonwealth Bank of Australia and holds positions at Macquarie University Council and EXL APAC Advisory Council.
As an Independent Non-Executive Director, Cobley will contribute to Mesoblast's growth during key milestones, including commercialization expansion and development of treatments for highly prevalent diseases. Board Chair Jane Bell highlighted Cobley's extensive corporate finance and governance experience in regulated industries as valuable assets for the company's future.
Mesoblast, leader mondiale nelle medicine cellulari alloogene, ha nominato Lyn Cobley nel suo Consiglio di Amministrazione. Cobley vanta oltre 30 anni di esperienza nei servizi finanziari, avendo ricoperto il ruolo di CEO di Westpac Institutional Bank e di Tesoriere del Gruppo presso Commonwealth Bank of Australia.
La nomina segue la recente approvazione da parte della FDA di Ryoncil® da parte di Mesoblast. Attualmente, Cobley è direttore di Commonwealth Bank of Australia e ricopre incarichi presso il Consiglio dell'Università di Macquarie e il Consiglio Consultivo EXL APAC.
In qualità di Direttore Indipendente Non Esecutivo, Cobley contribuirà alla crescita di Mesoblast durante tappe fondamentali, tra cui l'espansione commerciale e lo sviluppo di trattamenti per malattie altamente diffuse. La Presidente del Consiglio, Jane Bell, ha sottolineato come l'ampia esperienza di Cobley in finanza aziendale e governance in settori regolamentati rappresenti un valore importante per il futuro dell'azienda.
Mesoblast, líder mundial en medicamentos celulares alogénicos, ha nombrado a Lyn Cobley en su Junta Directiva. Cobley aporta más de 30 años de experiencia en servicios financieros, habiendo sido CEO de Westpac Institutional Bank y Tesorero del Grupo en Commonwealth Bank of Australia.
El nombramiento se produce tras la reciente aprobación por parte de la FDA de Ryoncil® por parte de Mesoblast. Actualmente, Cobley es director de Commonwealth Bank of Australia y ocupa cargos en el Consejo de la Universidad de Macquarie y en el Consejo Asesor de EXL APAC.
Como Directora Independiente No Ejecutiva, Cobley contribuirá al crecimiento de Mesoblast durante hitos clave, incluyendo la expansión comercial y el desarrollo de tratamientos para enfermedades altamente prevalentes. La presidenta de la Junta, Jane Bell, destacó la amplia experiencia de Cobley en finanzas corporativas y gobernanza en industrias reguladas como un activo valioso para el futuro de la compañía.
Mesoblast는 동종 세포 치료제 분야의 글로벌 선두 기업으로서 Lyn Cobley를 이사회에 임명했습니다. Cobley는 Westpac Institutional Bank의 CEO와 Commonwealth Bank of Australia의 그룹 재무담당 이사를 역임하며 30년 이상의 금융 서비스 경력을 보유하고 있습니다.
이번 임명은 Mesoblast가 최근 FDA로부터 Ryoncil® 승인을 받은 데 따른 것입니다. Cobley는 현재 Commonwealth Bank of Australia 이사이며, Macquarie 대학 이사회 및 EXL APAC 자문위원회에서도 활동하고 있습니다.
독립 비상임 이사로서 Cobley는 상업화 확대와 고유병 치료제 개발 등 중요한 이정표에서 Mesoblast의 성장에 기여할 예정입니다. 이사회 의장 Jane Bell은 규제 산업에서의 풍부한 기업 금융 및 거버넌스 경험이 회사의 미래에 큰 자산이 될 것이라고 강조했습니다.
Mesoblast, leader mondial des médicaments cellulaires allogéniques, a nommé Lyn Cobley au sein de son Conseil d'administration. Cobley apporte plus de 30 ans d'expérience dans les services financiers, ayant été CEO de Westpac Institutional Bank et trésorière du groupe Commonwealth Bank of Australia.
Cette nomination fait suite à la récente approbation par la FDA de Ryoncil® par Mesoblast. Cobley est actuellement administratrice de Commonwealth Bank of Australia et siège au Conseil de l'Université Macquarie ainsi qu'au Conseil consultatif EXL APAC.
En tant qu'administratrice indépendante non exécutive, Cobley contribuera à la croissance de Mesoblast lors d'étapes clés, notamment l'expansion commerciale et le développement de traitements pour des maladies très répandues. La présidente du Conseil, Jane Bell, a souligné que l'expérience étendue de Cobley en finance d'entreprise et gouvernance dans des secteurs réglementés constitue un atout précieux pour l'avenir de l'entreprise.
Mesoblast, ein weltweit führendes Unternehmen im Bereich allogener Zelltherapien, hat Lyn Cobley in seinen Vorstand berufen. Cobley bringt über 30 Jahre Erfahrung im Finanzdienstleistungssektor mit, darunter als CEO der Westpac Institutional Bank und Group Treasurer der Commonwealth Bank of Australia.
Die Ernennung erfolgt nach der kürzlichen FDA-Zulassung von Ryoncil® durch Mesoblast. Cobley ist derzeit Direktor der Commonwealth Bank of Australia und Mitglied des Macquarie University Council sowie des EXL APAC Advisory Council.
Als unabhängiges nicht-geschäftsführendes Vorstandsmitglied wird Cobley Mesoblasts Wachstum während wichtiger Meilensteine unterstützen, darunter die Erweiterung der Kommerzialisierung und die Entwicklung von Behandlungen für weit verbreitete Krankheiten. Vorstandsvorsitzende Jane Bell hob Cobleys umfangreiche Erfahrung in Unternehmensfinanzierung und Governance in regulierten Branchen als wertvolle Ressource für die Zukunft des Unternehmens hervor.
- FDA approval of Ryoncil® product secured
- Strategic board appointment of experienced financial leader with 30+ years in banking
- Multiple near-term revenue opportunities through commercialization and new indications
- Company positioned as global leader in allogeneic cell therapy industry
- None.
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years’ experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.
Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie University Council, where she chairs the Finance and Facilities Committee, and an Advisory Member, EXL APAC Advisory Council. She is a former director of the Australian Financial Markets Association.
Commenting on her appointment Ms. Cobley said, “Following the recent United States Food and Drug Administration (FDA) approval of Ryoncil®, Mesoblast has become a wonderful success story for not only the Australian biotechnology industry but the global leader in the allogeneic cell therapy industry. The Company has many exciting milestones in the near-term including ramp-up of commercialization and additional indications for some highly prevalent diseases. I look forward to contributing to the ongoing development and success of Mesoblast in the coming years.”
Mesoblast Chair Jane Bell welcomed Ms. Cobley to the Board, “We are delighted to have Lyn join Mesoblast as an Independent Non-Executive Director. She has extensive corporate finance and governance experience at some of the largest institutions globally and brings a strong background in strategy and leadership, and working in highly regulated industries.”
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Allison Worldwide | BlueDot Media |
| Emma Neal | Steve Dabkowski |
| T: +1 603 545 4843 | T: +61 419 880 486 |
| E: emma.neal@allisonworldwide.com | E: steve@bluedot.net.au |
FAQ
Who is Lyn Cobley joining Mesoblast (MESO) and what is her background?
What recent FDA approval did Mesoblast (MESO) receive for Ryoncil?
What are Lyn Cobley's current board positions besides Mesoblast (MESO)?
What upcoming milestones does Mesoblast (MESO) have planned?
How will Lyn Cobley's experience benefit Mesoblast (MESO)?
